|
1
|
Arndt CA and Crist WM: Common
musculoskeletal tumors of childhood and adolescence. N Engl J Med.
341:342–352. 1999.
|
|
2
|
Friedman MA and Carter SK: The therapy of
osteogenic sarcoma: current status and thoughts for the future. J
Surg Oncol. 4:482–510. 1972.
|
|
3
|
Ozaki T, Flege S, Kevric M, et al:
Osteosarcoma of the pelvis: experience of the Cooperative
Osteosarcoma Study Group. J Clin Oncol. 21:334–341. 2003.
|
|
4
|
Tabone MD, Kalifa C, Rodary C, et al:
Osteosarcoma recurrences in pediatric patients previously treated
with intensive chemotherapy. J Clin Oncol. 12:2614–2620. 1994.
|
|
5
|
Kempf-Bielack B, Bielack SS, Jürgens H, et
al: Osteosarcoma relapse after combined modality therapy: an
analysis of unselected patients in the Cooperative Osteosarcoma
Study Group (COSS). J Clin Oncol. 23:559–568. 2005.
|
|
6
|
Biccoli A, Rocca M, Salone M, et al:
Resection of recurrent pulmonary metastases in patients with
osteosarcoma. Cancer. 104:1721–1725. 2005.
|
|
7
|
Bielack SS, Kempf-Bielack B, Branscheid D,
et al: Second and subsequent recurrences of osteosarcoma:
presentation, treatment, and outcomes of 249 consecutive
cooperative osteosarcoma study group patients. J Clin Oncol.
27:557–565. 2009.
|
|
8
|
Briccoli A, Rocca M, Salone M, et al: High
grade osteosarcoma of the extremities metastatic to the lung:
long-term results in 323 patients treated combining surgery and
chemotherapy, 1985–2005. Surg Oncol. 19:193–199. 2010.
|
|
9
|
Zhang Y, Xiao JP, Zhang HZ, et al:
Stereotactic body radiation therapy favors long-term overall
survival in patients with lung metastases: five-year experience of
a single-institution. Chin Med J (Engl). 124:4132–4137. 2011.
|
|
10
|
Hogendoorn PC, Athanasou N and Bielack S;
ESMO/EUROBONET Working Group. Bone sarcomas: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
21(Suppl 5): 204–213. 2010.
|
|
11
|
Qi WX, He AN, Tang LN, Shen Z and Yao Y:
Evaluation of pirarubicin-cisplatin chemotherapy in the treatment
for refractory and recurrent high-grade osteosarcoma: experience of
a single institute. Med Oncol. 29:2229–2233. 2012.
|
|
12
|
Seibel NL, Krailo M, Chen Z, et al:
Upfront window trial of topotecan in previously untreated children
and adolescents with poor prognosis metastatic osteosarcoma:
children’s Cancer Group (CCG) 7943. Cancer. 109:1646–1653.
2007.
|
|
13
|
Crews KR, Stewart CF, Liu T, Rodriguez
Galindo C, Santana VM and Daw NC: Effect of fractionated ifosfamide
on the pharmacokinetics of irinotecan in pediatric patients with
osteosarcoma. J Pediatr Hematol Oncol. 26:764–767. 2004.
|
|
14
|
Bond M, Bernstein ML, Pappo A, Schultz KR,
Krailo M, et al: A phase II study of imatinib mesylate in children
with refractory or relapsed solid tumors: A Children’s Oncology
Group study. Pediatr Blood Cancer. 50:254–258. 2008.
|
|
15
|
De Sio L, Milano GM, Castellano A, Jenkner
A, Fidani P, et al: Temozolamide in resistant or relapsed pediatric
solid tumors. Pediatr Blood Cancer. 47:30–36. 2006.
|
|
16
|
Carmichael J: The role of gemcitabine in
the treatment of other tumours. Br J Cancer. 78(Suppl 3): 21–25.
1998.
|
|
17
|
Trudeau ME: Docetaxel: a review of its
pharmacology and clinical activity. Can J Oncol. 6:443–457.
1996.
|
|
18
|
Merimsky O, Meller I, Kollender Y and
Inbar M: Palliative effect of gemcitabine in osteosarcoma resistant
to standard chemotherapy. Eur J Cancer. 34:1296–1297. 1998.
|
|
19
|
Okuno S, Edmonson J, Mahoney M, Buckner
JC, Frytak S and Galanis E: Phase II trial of gemcitabine in
advanced sarcomas. Cancer. 94:3225–3229. 2002.
|
|
20
|
Leu KM, Ostruszka LJ, Shewach D, et al:
Laboratory and clinical evidence of synergistic cytotoxicity of
sequential treatment with gemcitabine followed by docetaxel in the
treatment of sarcoma. J Clin Oncol. 22:1706–1712. 2004.
|
|
21
|
Navid F, Willert JR, McCarville MB, et al:
Combination of gemcitabine and docetaxel in the treatment of
children and young adults with refractory bone sarcoma. Cancer.
113:419–425. 2008.
|
|
22
|
Mora J, Cruz CO, Parareda A and de Torres
C: Treatment of relapsed/refractory pediatric sarcomas with
gemcitabine and docetaxel. J Pediatr Hematol Oncol. 31:723–729.
2009.
|
|
23
|
Geoerger B, Chisholm J, Le Deley MC, et
al: European Consortium Innovative Therapies for Children with
Cancer: Phase II study of gemcitabine combined with oxaliplatin in
relapsed or refractory paediatric solid malignancies: An innovative
therapy for children with Cancer European Consortium Study. Eur J
Cancer. 47:230–238. 2011.
|
|
24
|
Qi WX, He AN, Tang LN, et al: Efficacy and
safety of gemcitabine-docetaxel combination therapy for recurrent
or refractory high-grade osteosarcoma in China: a retrospective
study of 18 patients. Jpn J Clin Oncol. 42:427–431. 2012.
|
|
25
|
He A, Qi W, Huang Y, et al: Comparison of
pirarubicin-based versus gemcitabine-docetaxel chemotherapy for
relapsed and refractory osteosarcoma: a single institution
experience. Int J Clin Oncol. 18:498–505. 2013.
|
|
26
|
Shih C, Habeck LL, Mendelsohn LG, et al:
Multiple folate enzyme inhibition: mechanism of a novel
pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme
Regul. 38:135–152. 1998.
|
|
27
|
Hartmann JT, Bauer S, Egerer G, et al:
Pemetrexed in patients with refractory soft tissue sarcoma: a
non-comparative multicenter phase II study of the German Sarcoma
Group AIO-STS 005. Invest New Drugs. 31:167–174. 2013.
|
|
28
|
Argiris A, Pennella E, Koustenis A, et al:
Pemetrexed in head and neck cancer: a systematic review. Oral
Oncol. 49:492–501. 2013.
|
|
29
|
Tomasini P, Greillier L, Khobta N and
Barlesi F: The place of pemetrexed in the management of
non-small-cell lung cancer patients. Expert Rev Anticancer Ther.
13:257–266. 2013.
|
|
30
|
Boons CC, VAN Tulder MW, Burgers JA, et
al: The value of pemetrexed for the treatment of malignant pleural
mesothelioma: a comprehensive review. Anticancer Res. 33:3553–3561.
2013.
|
|
31
|
Walling J: From methotrexate to pemetrexed
and beyond. A review of the pharmacodynamic and clinical properties
of antifolates. Invest New Drugs. 24:37–77. 2006.
|
|
32
|
Duffaud F, Egerer G, Ferrari S, et al: A
phase II trial of second-line pemetrexed in adults with
advanced/metastatic osteosarcoma. Eur J Cancer. 48:564–570.
2012.
|
|
33
|
Urba S, van Herpen CM, Sahoo TP, et al:
Pemetrexed in combination with cisplatin versus cisplatin
monotherapy in patients with recurrent or metastatic head and neck
cancer: final results of a randomized, double-blind,
placebo-controlled, phase 3 study. Cancer. 118:4694–4705. 2012.
|
|
34
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
et al: Phase III study of pemetrexed in combination with cisplatin
versus cisplatin alone in patients with malignant pleural
mesothelioma. J Clin Oncol. 21:2636–2644. 2003.
|
|
35
|
Jänne PA, Wozniak AJ, Belani CP, et al:
Pemetrexed expanded access program investigators: Pemetrexed alone
or in combination with cisplatin in previously treated malignant
pleural mesothelioma: outcomes from a phase IIIB expanded access
program. J Thorac Oncol. 1:506–512. 2006.
|
|
36
|
Trotti A, Byhardt R, Stetz J, et al:
Common toxicity criteria: version 2.0. an improved reference for
grading the acute effects of cancer treatment: impact on
radiotherapy. Int J Radiat Oncol Biol Phys. 47:13–47. 2000.
|
|
37
|
Cirillo M, Venturini M, Ciccarelli L, et
al: Clinician versus nurse symptom reporting using the National
Cancer Institute-Common Terminology Criteria for Adverse Events
during chemotherapy: results of a comparison based on patient’s
self-reported questionnaire. Ann Oncol. 20:1929–1935. 2009.
|
|
38
|
Bacci G, Briccoli A, Ferrari S, et al:
Neoadjuvant chemotherapy for osteosarcoma of the extremity:
long-term results of the Rizzoli’s 4th protocol. Eur J Cancer.
37:2030–2039. 2001.
|
|
39
|
Bacci G, Ferrari S, Longhi A, et al:
Italian Sarcoma Group/Scandinavian Sarcoma Group: High dose
ifosfamide in combination with high dose methotrexate, adriamycin
and cisplatin in the neoadjuvant treatment of extremity
osteosarcoma: preliminary results of an Italian Sarcoma
Group/Scandinavian Sarcoma Group pilot study. J Chemother.
14:198–206. 2002.
|
